Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: A review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 5, 2001, Pages 505-511

  Amaral, Leonard ^a   Kristiansen, Jette E ^b   Viveiros, Miguel ^a   Atouguia, Jorge ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b Klinisk Mikrobiologisk Afdeling   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DESIPRAMINE; ETHAMBUTOL; ISONIAZID; LEVOMEPROMAZINE; METHDILAZINE; METHYLENE BLUE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PROMETHAZINE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIORIDAZINE; TRIFLUOPERAZINE; TUBERCULOSTATIC AGENT;

AGRANULOCYTOSIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; CONJUNCTIVITIS; CONTROLLED STUDY; DROWSINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KERATOPATHY; LIVER INJURY; LONG TERM CARE; LUNG TUBERCULOSIS; MACROPHAGE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTOSIS; PHOTOALLERGY; PHOTOTOXICITY; RETINOPATHY; REVIEW;

EID: 0035010729     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.5.505     Document Type: Review

References (53)

1. World Health Organization. (1998). Anti-tuberculosis Drug Resistance in the World. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO, Geneva, Switzerland.
2. Anonymous. (1993). Initial therapy for tuberculosis in the era of multi-drug resistance: Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbidity and Mortality Weekly Report 42, 1-8.
3. Liu, Z., Shilkret, K. L. & Finelli, L. (1998). Initial drug regimens for the treatment of tuberculosis; evaluation of physician prescribing practices in New Jersey, 1994-1995. Chest 113, 1446-51.
4. Mitchison, D. A. (1998). How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. International Journal Tuberculosis and Lung Disease 2, 10-5.
5. Kristiansen, J. E. & Amaral, L. (1997). The potential management of resistant infections with non-antibiotics. Journal of Antimicrobial Chemotherapy 40, 319-27.
6. Guttmann, P. & Ehrlich, P. (1891). Uber die wirkung des Methylenblau bei Malaria. Berliner Klinika Wochenschrift 39, 953-6.
7. Erhlich, P. (1913). Chemotherapeutics: scientific principles, methods and results. Lancet ii, 445-51.
8. hi benBodoni, P. (1899). Dell'azione sedativa del bleu di metilene in vaire forme di psicosi. Clinica Medica Italiana 24, 217-22.
9. Kristiansen, J. E. (1989). Dyes, antipsychotic drugs and antimicrobial activity. Danish Medical Bulletin 36, 178-85.
10. Charpentier, P., Gaillot, P., Jacob, R., Gaudecho, J. & Buisson, P. (1952). Recherches sur les di-methylaminopropyl-N-phenothiazines. Comptes Rendues de l'Academie des Sciences 235, 59-60.
11. Geiger, H. & Finkelstein, B. A. (1954). Largactil in the treatment of tuberculosis. Schweizerische Medizinische Wochenschrift 84, 1063-4.
12. Spitz, H. & Levitt, R. (1956). On the question of how Largactil works against M. tuberculosis. Schweizerische Medizinische Wochenschrift 86, 869.
13. Fisher, R. A. & Teller, E. (1959). Clinical experience with ataractic therapy in tuberculous psychiatric patients. Disease Chest 34, 134-9.
14. Kamisnka, M. (1967). Role of chlorpromazine in the treatment of pulmonary tuberculosis in psychiatric patients. Folia Medica Cracoviensia 9, 115-43.
15. Levaditi, C., Chaigneau-Erhard, H. & Henry-Eveno, J. (1951). L'antihistaminique 3277 RP (Phenergan) agit-il curativement dans la tuberculose experimentale de la souris? Comptes Rendues de l'Societe Biologique 145, 1454-6.
16. Bourdon, J. L. (1961). Contribution to the study of the antibiotic properties of chlorpromazine or 4560 RP. Annales de l'Institut Pasteur 101, 876-86.
17. Courmont, P. & Derries, G. (1951). Action antibiotique in vitro du 3277 RP sur le bacille de Koch? Comptes Rendues de l'Societe Biologique 145, 335-8.
18. Crowle, J. A., Douvas, G. S. & May, M. H. (1992). Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemotherapy 38, 410-9.
19. Molnar, J., Beladi, I. & Foldes, I. (1977). Studies on anti-tuberculotic action of some phenothiazine derivatives in vitro. Zentralblatt fur Backteriologie (Orig A) 239, 521-6.
20. Kristiansen, J. E. & Vergmann, B. (1986). The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta Pathologica Microbiologica Immunologica Scandinavica (B) 94, 393-8.
21. Amaral, L., Kristiansen, J. E., Abebe, L. S. & Millett, W. (1996). Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. Journal of Antimicrobial Chemotherapy 38, 1049-53.
22. Chakrabarty, A. N., Bhattacharya, C. P. & Dastidar, S. G. (1993). Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine. APMIS 101, 449-54.
23. Guth, P. S. & Spirtes, M. A. (1964). The phenothiazine tranquilizers: biochemical and biophysical actions. International Review of Neurobiology 7, 231-78.
24. Amaral, L. & Kristiansen, J. E. (2000). Phenothiazines: an alternative to conventional therapy for the initial management of multidrug resistant tuberculosis. A call for studies. International Journal of Antimicrobial Agents 14, 173-6.
25. Salih, F. A., Kaushik, N. K., Sharma, P., Choudary, G. V., Murthy, P. S. & Venkitasubramanian, T. A. (1991). Calmodulin-like activity in mycobacteria. Indian Journal of Biochemistry and Biophysics 28, 491-5.
26. Ratnakar, P. & Murthy P. S. (1992). Antitubercular activity of trifluoperazine, acalmodulin antagonist. FEMS Microbiology Letters 76, 73-6.
27. Ratnakar, P. & Murthy, P. S. (1993). Trifluoperazine inhibits the incorporation of labelled precursors into lipids, proteins and DNA of Mycobacterium tuberculosis H37Rv. FEMS Microbiology Letters 110, 291-4.
28. Ratnakar P., Rao, S. P., Sriramarao, P. & Murthy, P. S. (1995). Structure - antitubercular activity relationship of phenothiazine-type calmodulin antagonists. International Clinical Psychopharmacology 10, 39-43.
29. Gadre, D. V., Talwar, V., Gupta, H. C. & Murthy, P. S. (1998). Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis. International Clinical Psychopharmacology 13, 129-31.
30. Gadre, D. V. & Talwar, V. (1999). In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine. Journal of Chemotherapy 11, 203-6.
31. Viveiros, M. B., Bosne-David, S. & Amaral, L. (2000). Comparative in vitro activity of phenothiazines against multi-drug resistant Mycobacterium tuberculosis. International Journal of Antimicrobial Agents 16, 69-71.
32. Viveiros, M. B. & Amaral, L. (2001). Enhancement of antibiotic activity against polydrug-resistant Mycobacterium tuberculosis by phenothiazines. International Journal of Antimicrobial Agents 17, 225-8.
33. Sherman, L. F., Fujiwara, P. I., Cook, S. V., Bazerman, L. B. & Frieden T. R. (1999). Patient and health care system delays in the diagnosis and treatment of tuberculosis. International Journal of Tuberculosis and Lung Disease 3, 1088-95.
34. Roufogalis, B. D., Minocherhomjee, A. & Al-Jobore, A. (1983). Pharmacological antagonism of calmodulin. Canadian Journal of Biochemistry and Cell Biology 61, 927-33.
35. Motohashi, N. (1991). Phenothiazines and calmodulin. Anticancer Research 11, 1125-64.
36. Hidaka, H. & Naito, Y. (1998). Inhibitor of calmodulin and calmodulin dependent enzymes. Tanpakushitsu Kakusan Koso 43, Suppl. 12, 1732-8.
37. Elferink, J. G. R. (1979). Chlorpromazine inhibits phagocytosis and exocytosis in rabbit polymorphonuclear leukocytes. Biochemical Pharmacology 28, 965-8.
38. Ghezzi, P. (1991). Effects of chlorpromazine on polymorphonucleocyte-mediated activities in vivo and in vitro. Immunology 72, 138-43.
39. Garcia-Rodriguez, L. A., Ruigomez, A. & Jick, H. (1997). A review of epidemiologic research on drug-induced acute liver injury using general practice research data base in the United Kingdom. Pharmacotherapy 17, 721-8.
40. Kaplowitz, N., Aw, T. Y., Simon, F. R. & Stoltz, A. (1986). Drug-induced hepatotoxicity. Annals of Internal Medicine 104, 826-39.
41. Pisciotta, V. (1978). Drug induced agranulocytosis. Drugs 15, 132-43.
42. Marmor, M. F. (1990). Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. British Journal of Ophthalmology 74, 739-42.
43. Studenik, C., Lemmens-Gruber, R. & Heistracher, P. (1999). Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. European Journal of Pharmaceutical Sciences 7, 113-8.
44. Schmidt, W. & Lang, K. (1997). Life-threateninig dysrhythmias in severe thioridazine poisoning treated with physostigmine and transient atrial pacing. Critical Care Medicine 25, 1925-30.
45. Carrillo, J. A., Ramos, S. I., Herraiz, A. G., Llerena, A., Agundez, J. A., Berecz, R. et al. (1999). Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. Journal of Clinical Psychopharmacology 19, 494-9.
46. Heiman, E. M. (1977). Cardiac toxicity with thioridazine - tricyclic antidepressant combination. Journal of Nervous and Mental Disease 165, 139-43.
47. Frieden, T. R. (1999). Direct observed therapy and tuberculosis treatment completion. American Journal of Public Health 89, 604-5.
48. De Cock, K. M. & Chaisson, R. E. (1999). Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. International Journal of Tuberculosis and Lung Disease 3, 457-65.
49. Schraufnagel, D. E. (1999). Tuberculosis treatment for the beginning of the next century. International Journal of Tuberculosis and Lung Disease 3, 651-62.
50. Reddy, P. H., Burra, S. S. & Murthy, P. S. (1992). Correlation between calmodulin-like protein, phospholipids, and growth in glucose-grown Mycobacterium phlei. Canadian Journal of Microbiology 38, 339-42.
51. Dhople, A. M. (1999). In vitro activities of phenothiazine-type calmodulin antagonists against Mycobacterium leprae. Microbios 98, 113-21.
52. Jaanus, S. D. (1992). Ocular side effects of selected systemic drugs. Optometry Clinics 2, 73-96.
53. Chignell, C. F., Motten, A. G. & Buettner, G. R. (1985). Photo-induced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environmental Health Perspectives 64, 103-10.